Dermatofibrosarcoma protuberans: A surgical disease with a molecular savior

Current Opinion in Oncology

Volumn 18, Issue 4, 2006, Pages 341-346

  McArthur, Grant A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Dermatofibrosarcoma protuberans; Imatinib; Platelet derived growth factor receptor; Surgery; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOMAL LOCALIZATION; CHROMOSOME REARRANGEMENT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DERMATOFIBROSARCOMA PROTUBERANS; ECHOGRAPHY; FOLLOW UP; GENE EXPRESSION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; OUTCOME ASSESSMENT; PATHOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SURGICAL TECHNIQUE;

ADULT; ANTINEOPLASTIC AGENTS; DERMATOFIBROSARCOMA; HUMANS; MIDDLE AGED; MODELS, GENETIC; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-SIS; PYRIMIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33748068096     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000228739.62756.df     Document Type: Review

References (45)

1. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346:683-693.
2. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-1167.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
4. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000; 88:2711-2720.
5. Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 2005; 23:7669-7675. The largest published single-center series of outcomes in DFSP. Clearly demonstrates that surgery alone can give disease control in over 90% of cases.
6. Checketts SR, Hamilton TK, Baughman RD. Congenital and childhood dermatofibrosarcoma protuberans: a case report and review of the literature. J Am Acad Dermatol 2000; 42 (5 Pt 2):907-913.
7. Weinstein JM, Drolet BA, Esterly NB, et al. Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol 2003; 139:207-211.
8. Thornton SL, Reid J, Papay FA, Vidimos AT. Childhood dermatofibrosarcoma protuberans: role of preoperative imaging. J Am Acad Dermatol 2005; 53:76-83. Small series supporting a role for magnetic resonance imaging in preoperative assessment.
9. Personal communication of unpublished data, National Cancer Statistics Clearing House, Australian Institute of Health and Welfare.
10. Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004; 30:341-345.
11. Hsi ED, Nickoloff BJ. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles. J Dermatol Sci 1996; 11:1-9.
12. Haycox CL, Odland PB, Olbricht SM, Piepkorn M. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 1997; 37 (3 Pt 1):438-444.
13. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ('high-grade') dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998; 22:576-587.
14. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997; 15:95-98.
15. O'Brien KP, Seroussi E, Dal Cin P, et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998; 23:187-193.
16. Wang J, Hisaoka M, Shimajiri S, et al. Detection of COL1A1-PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription- polymerase chain reaction using archival formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol 1999; 8:113-119.
17. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 2003; 140:1-12.
18. Linn SC, West RB, Pollack JR, et al. Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 2003; 163:2383-2395.
19. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999; 59:3719-3723.
20. Simon MP, Navarro M, Roux D, Pouyssegur J. Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q131) in Dermatofibrosarcoma protuberans (DP). Oncogene 2001; 20:2965-2975.
21. Gisselsson D, Hoglund M, O'Brien KP, et al. A case of dermatofibrosarcoma protuberans with a ring chromosome 5 and a rearranged chromosome 22 containing amplified COL1A1 and PDGFB sequences. Cancer Lett 1998; 133:129-134.
22. Sonobe H, Furihata M, Iwata J, et al. Dermatofibrosarcoma protuberans harboring t(9;22)(q32;q12.2) Cancer Genet Cytogenet 1999; 110:14-18.
23. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005; 23:866-873. Important paper defining a role for targeted therapy imatinib in unresectable DFSP. Correlates the presence of t(17;22) with response to imatinib.
24. Taylor HB, Helwig EB. Dermatofibrosarcoma protuberans A study of 115 cases. Cancer 1962; 15:717-725.
25. Parker TL, Zitelli JA. Surgical margins for excision of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1995; 32 (2 Pt 1):233-236.
26. Gloster HM Jr, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996; 35:82-87.
27. Nouri K, Lodha R, Jimenez G, Robins P. Mohs micrographic surgery for dermatofibrosarcoma protuberans: University of Miami and NYU experience. Dermatol Surg 2002; 28:1060-1064; discussion 1064.
28. Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004; 101:28-38.
29. Torreggiani WC, Al-Ismail K, Munk PL, et al. Dermatofibrosarcoma protuberans: MR imaging features. AJR Am J Roentgenol 2002; 178:989-893.
30. Suit H, Spiro I, Mankin HJ, et al. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol 1996; 14:2365-2369.
31. Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 2000; 57:175-181.
32. Ballo MT, Zagars GK, Pisters P, Pollack A. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998; 40:823-827.
33. Dagan R, Morris CG, Zlotecki RA, et al. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol 2005; 28:537-539. Reports very good clinical outcomes of adding radiotherapy to surgery for high-risk localized DFSP.
34. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1:493-502.
35. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105:3127-3132.
36. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347:481-487.
37. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002; 20:3586-3591.
38. Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002; 100:623-626.
39. Labropoulos S, Papadopoulos S, Hadjiyiassemi L, et al. Response of metastatic dermatofibrosarcoma protuberans to imatinib mesylate. Proc Am Soc Clin Oncol 2003; 830:830 (abstr 3334).
40. Mizutani K, Tamada Y, Hara K, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004; 151:235-237.
41. Labropoulos SV, Fletcher JA, Oliveira AM, et al. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005; 16:461-466. Interesting case report of sustained complete response in a patient with low-volume metastatic DFSP.
42. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337.
43. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
44. Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996; 35 (3 Pt 1):355-374; quiz 375-376.
45. Ng A, Nishikawa H, Lander A, Grundy R. Chemosensitivity in pediatric dermatofibrosarcoma protuberans. J Pediatr Hematol Oncol 2005; 27:100-1002.